Palabras clave
diabetes mellitus
infecciones estreptocócicas
Cómo citar
Resumen
La enfermedad por neumococo se define como cualquier infección causada por la bacteria Streptococcus pneumoniae; esta se denomina invasiva cuando el aislamiento de este microorganismo se confirma en sitios corporales que son normalmente estériles, tales como la sangre y el líquido cefalorraquídeo, y no invasiva cuando la infección se produce en sitio corporal es que normalmente no son estériles. La enfermedad renal crónica y la diabetes mellitus son factores de riesgo importantes para el desarrollo de enfermedad neumocócica debido a su estado de inmunosupresión, por lo que la vacunación antineumocócica es una medida preventiva fundamental en los pacientes que padecen estas condiciones.
Citas
Vandecasteele SJ, Ombelet S, Blumental S, Peetermans WE. The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease. Clin Kidney J. junio de 2015;8(3):318-24.
Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges of pneu-mococcal disease in adults. Eur Respir Rev. 2012;21(123):57-65. https://dx.doi.org/10.1183/09059180.00008911.
Aliberti S, Mantero M, Mirsaeidi M, Blasi F. The role of vaccination in preventing pneumococcal disease in adults. Clin Microbiol Infect. mayo de 2014;20(0 5):52-8.
Varon E, Mainardi JL, Gutmann L. Streptococcus pneumoniae: still a major pathogen. ClinMicrobiol Infect. 2010;16(5):401. https://dx.doi.org/10.1111/j.1469-0691.2010.03190.x
Drijkoningen JJC, Rohde GGU. Pneumococcal infection in adults: burden of disease. Clinical Microbiology and Infection. mayo de 2014;20:45-51. https://dx.doi.org/10.1111/1469-0691.12461
Marston BJ, Plouffe JF, File TM, Hackman BA, Salstrom SJ, Lipman HB, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med. 11 de agosto de 1997;157(15):1709-18.
Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination. New England Journal of Medicine. 11 de julio de 2013;369(2):155-63.
Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D,et al. Effect of theintroduction of pneumococcal conjugate vaccination on invasive pneumococcal disease inThe Gambia: a population-based surveillance study. Lancet Infect Dis. 2016;16(6):703-11.https://dx.doi.org/10.1016/s1473-3099(16)00054-2.
Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA. 4 de abril de 2001;285(13):1729-35 https://dx.doi.org/10.1001/jama.285.13.1729
Marston BJ, Plouffe JF, File TM, Hackman BA, Salstrom SJ, Lipman HB,et al.Incidence ofCommunity-Acquired Pneumonia Requiring Hospitalization. Results of a Population-BasedActive Surveillance Study in Ohio. Arch Intern Med. 1997;157(15):1709-18. https://dx.doi.org/10.1001/archinte.1997.00440360129015
Bonnave C, Mertens D, Peetermans W, Cobbaert K, Ghesquiere B, Deschodt M, et al. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe. Eur J Clin Microbiol Infect Dis [Internet]. abril de 2019 [citado 9 de agosto de 2020];38(4):785-91. Disponible en: http://link.springer.com/10.1007/s10096-019-03485-3
Cruickshank HC, Jefferies JM, Clarke SC. Lifestyle risk factors for invasive pneumococcal disease: a systematic review. BMJ Open [Internet]. 20 de junio de 2014 [citado 9 de agosto de 2020];4(6):e005224-e005224. Disponible en: http://bmjopen.bmj.com/cgi/doi/10.1136/bmjopen-2014-005224
Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: Table 1. Thorax [Internet]. octubre de 2015 [citado 9 de agosto de 2020];70(10):984-9. Disponible en: http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2015-206780
Mor A, Thomsen RW, Ulrichsen SP, Sørensen HT. Chronic heart failure and risk of hospi-talization with pneumonia: A population-based study. Eur J Intern Med. 2013;24(4):349-53.https://dx.doi.org/10.1016/j.ejim.2013.02.013.
Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of Pneu-mococcal Disease in Adults With Chronic Medical Conditions. Open Forum Infect Dis.2014;1(1):ofu024. https://dx.doi.org/10.1093/o/ofu024.
Juthani-Mehta M, De Rekeneire N, Allore H, Chen S, O’Leary JR, Bauer DC,et al.Modia-ble Risk Factors for Pneumonia Requiring Hospitalization of Community-Dwelling OlderAdults: The Health, Aging, and Body Composition Study. J Am Geriatr Soc. 2013;61(7):1111-8. https://dx.doi.org/10.1111/jgs.12325.
Ochoa-Gondar O, Vila-Corcoles A, de Diego C, Arija V, Maxenchs M, Grive M,et al. Theburden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study. BMCPublic Health. 2008;8:222. https://dx.doi.org/10.1186/1471-2458-8-222.
Jaume A, Salle F, Devita A, Martínez F, Sgarbi N. Fístula de líquido cefalorraquídeo pos-traumática: propuesta de algoritmo diagnóstico y terapéutico. Arch Med Int. 2015;37(1):47-52.
Gil-Prieto R, Garcia-Garcia L, Alvaro-Meca A, Mendez C, Garcia A, de Miguel AG. Theburden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine. 2011;29(3):412-6. https://dx.doi.org/10.1016/j.vaccine.2010.11.025
Chidiac C. Pneumococcal infections and adult with risk factors. Med Mal Infect.2012;42(10):517-24. https://dx.doi.org/10.1016/j.medmal.2012.04.003
Syed-Ahmed M, Narayanan M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Advances in Chronic Kidney Disease. enero de 2019;26(1):8-15. https://dx.doi.org/10.1053/j.ackd.2019.01.004
Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Nephrol. abril de 2019;23(4):437-47. https://dx.doi.org/10.1007/s10157-018-1641-8
Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J,et al. US Re-nal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the UnitedStates. Am J Kidney Dis. 2018;71(3 Suppl 1):A7. https://dx.doi.org/10.1053/j.ajkd.2018.01.002
James MT, Laupland KB, Tonelli M, Manns BJ, Culleton BF, Hemmelgarn BR. Risk ofBloodstream Infection in Patients With Chronic Kidney Disease Not Treated With Dialysis.Arch Intern Med. 2088;168(21):2333-9. https://dx.doi.org/10.1001/archinte.168.21.2333.
Dalrymple LS, Katz R, Kestenbaum B, de Boer IH, Fried L, Sarnak MJ,et al. The Riskof Infection-Related Hospitalization With Decreased Kidney Function. Am J Kidney Dis.2012;59(3):356-63. https://dx.doi.org/10.1053/j.ajkd.2011.07.012.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 7 de diciembre de 2017;12(12):2032-45.
Tesch GH. Diabetic nephropathy – is this an immune disorder? Clinical Science [Internet]. 15 de agosto de 2017 [citado 9 de agosto de 2020];131(16):2183-99. https://dx.doi.org/10.1042/CS20160636
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kid-ney Int. 2020;98(4S):S1–S115. https://dx.doi.org/10.1016/j.kint.2020.06.019.
Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabe-tic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care. 2005;28(1):164-76.https://dx.doi.org/10.2337/diacare.28.1.164.
Lim A. Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis.2014;7:361-81. https://dx.doi.org/10.2147/IJNRD.S40172.
Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. Am JKidney Dis. 2018;71(6):884-95. https://dx.doi.org/10.1053/j.ajkd.2017.10.026.
Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A reviewof pathogenesis. Indian J Endocr Metab. 2012;16(Suppl 1):s27-36. https://dx.doi.org/10.4103/2230-8210.94253.
Pahl MV, Vaziri ND. Immune Function in Chronic Kidney Disease. En: Chronic Renal Disease [Internet]. Elsevier; 2015 [citado 9 de agosto de 2020]. p. 285-97. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/B978012411602300024X
Krueger KM, Ison MG, Ghossein C. Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation. American Journal of Kidney Diseases. 1 de marzo de 2020;75(3):417-25. https://dx.doi.org/10.1053/j.ajkd.2019.06.014
Viasus D, Garcia-Vidal C, Cruzado JM, Adamuz J, Verdaguer R, Manresa F, et al. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrol Dial Transplant. septiembre de 2011;26(9):2899-906.
Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. septiembre de 2006;70(6):1135-41.
Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The Use of Vaccines in Adult Patients With Renal Disease. American Journal of Kidney Diseases. diciembre de 2005;46(6):997-1011.
Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest. diciembre de 2001;120(6):1883-7.
Portolés-Pérez J, Marqués-Vidas M, Marques-Vidas M, Picazo JJ, González- Romo F,García-Rojas A,et al. Recomendaciones de vacunación frente a neumococo en enfermos re-nales en España. Nefrología. 2014;34(5):545-692. https://doi.org/10.3265/Nefrologia.pre2014.May.12534
Ficha tecnica Prevenar 13 suspención inyectable. European Medicines Agency. ScienceMedicines Health; [citado julio 15 de 2013]. Disponible en: http://www.ema.europa.eu/docs/esES/documentlibrary/EPAR-ProductInformation/human/001104/WC500057247.pdf
Jefferies JMC, Macdonald E, Faust SN, Clarke SC. 13-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccin. octubre de 2011;7(10):1012-8. https://dx.doi.org/10.4161/hv.7.10.16794
Daniels CC, Rogers PD, Shelton CM. A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens. J Pediatr Pharmacol Ther. 2016;21(1):27-35. https://dx.doi.org/10.5863/1551-6776-21.1.27
Gilbertson DT, Guo H, Arneson TJ, Collins AJ. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. Nephrol Dial Transplant. septiembre de 2011;26(9):2934-9. https://dx.doi.org/10.1093/ndt/gfq853
Mahmoodi M, Aghamohammadi A, Rezaei N, Lessan-Pezeshki M, Pourmand G, Mohagheghi M-A, et al. Antibody response to pneumococcal capsular polysaccharide vaccination in patients with chronic kidney disease. European Cytokine Network. junio de 2009;20(2):69-74. https://dx.doi.org/10.1684/ecn.2009.0153
Mitra S, Stein GE, Bhupalam S, Havlichek DH. Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients 50 Years and Older with End-Stage Renal Disease and on Dialysis. Clin Vaccine Immunol. 4 de noviembre de 2016;23(11):884-7. https://dx.doi.org/10.1128/CVI.00153-16
Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y,et al.Aspects ofImmune Dysfunction in End-stage Renal Disease. Clin J Am Soc Nephrol. 2008;3(5):1526-33.https://dx.doi.org/10.2215/cjn.00950208.
DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S,et al. Stage of chronickidney disease predicts seroconversion after hepatitis B immunization: earlier is better. AmJ Kidney Dis. 2003;42(6):1184-92. https://dx.doi.org/10.1053/j.ajkd.2003.08.019.
Shen AK, Kelman JA, Warnock R, Zhang W, Brereton S, McKean S,et al.Beneciarycharacteristics and vaccinations in the end-stage renal disease Medicare beneciary popu-lation, an analysis of claims data 2006-2015. Vaccine, 2017;35(52):7302-8. https://dx.doi.org/10.1016/j.vaccine.2017.10.105
CKD Evaluation and Management – KDIGO [Internet]. [citado 1 de agosto de 2020]. Disponible en: https://kdigo.org/guidelines/ckd-evaluation-and-management/
Reddy S, Chitturi C, Yee J. Vaccination in Chronic Kidney Disease. Advances in Chronic Kidney Disease. enero de 2019;26(1):72-8 https://dx.doi.org/10.1053/j.ackd.2018.10.002
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.